The Global Drug Facility is the Stop TB Partnership's procurement and supply mechanism for tuberculosis diagnostics and treatment, created in 2001. It has grown into a one-stop bundled procurement service combining strategic purchasing of TB products and coordination of the market for them with technical assistance and capacity-building for national tuberculosis programmes. New treatments are added to its catalogue soon after approval, as with pretomanid, part of the shorter, all-oral drug-resistant TB regimens recommended by the World Health Organization, which the facility listed within a year of the drug's 2019 approval.
Facts
Connections
Associated With
Source pmc.ncbi.nlm.nih.gov: a unique, holistic and pioneering approach to drug procurement and management
Delivers Practice
Source pmc.ncbi.nlm.nih.gov: a unique, holistic and pioneering approach to drug procurement and management
In the Other Atlases
Addresses
Also in Medicine Atlas: the condition this subject addresses.
Source pmc.ncbi.nlm.nih.gov: a unique, holistic and pioneering approach to drug procurement and managementPage textQuote, Page text
The Global Drug Facility (GDF) for tuberculosis (TB) was launched on World TB Day 2001; it grew out of a declaration made a year earlier by countries attending the Ministerial Conference on TB and Sustainable Development in Amsterdam.
Found In
Also in Geography Atlas: where this subject is found.
Source pmc.ncbi.nlm.nih.gov: a unique, holistic and pioneering approach to drug procurement and managementAuthor affiliationsQuote, Author affiliations
a Stop TB Global Drug Facility, WHO, 20 avenue Appia, 1211 Geneva 27, Switzerland.
Sources
1. pmc.ncbi.nlm.nih.gov: a unique, holistic and pioneering approach to drug procurement and management
pmc.ncbi.nlm.nih.govPage text
The Global Drug Facility (GDF) for tuberculosis (TB) was launched on World TB Day 2001; it grew out of a declaration made a year earlier by countries attending the Ministerial Conference on TB and Sustainable Development in Amsterdam.
Delivers Practice: Disease Surveillance, Page text, program-kind-practice
While the kits do not represent a new tool for diagnosing TB, they are expected to serve as an effective interim measure to improve case finding until rapid diagnostic tools are available.
View the Source Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.